anemia

(redirected from transfusion-dependent anemia)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for anemia

References in periodicals archive ?
REVLIMID is also approved in the United States, Canada and several Latin American countries, as well as Malaysia, Israel, Japan, Australia and New Zealand for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
21 November 2011 - Celgene International Sarl, part of US Celgene Corp (NASDAQ:CELG), said today that the Swiss agency for Therapeutic Products (Swissmedic) had cleared REVLIMID (lenalidomide) to treat patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) related to a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.
REVLIMID is also approved in the United States, Canada and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
REVLIMID is currently approved for use in the US and Canada for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
A derivative of the drug thalidomide, Revlimid is FDA-approved for the treatment of transfusion-dependent anemia in patients with lower risk MDS who carry a specific chromosomal abnormality," says Azra Raza, M.
Full browser ?